Drug Profile
Finasteride/tamsulosin - GL PharmTech
Alternative Names: GL2701; Tamsulosin/finasterideLatest Information Update: 29 Jan 2019
Price :
$50
*
At a glance
- Originator GL PharmTech
- Class Amines; Androstenes; Antiandrogens; Antineoplastics; Azasteroids; Benzene derivatives; Ethers; Small molecules; Sulfonamides
- Mechanism of Action Alpha-1a adrenergic receptor antagonists; Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Benign prostatic hyperplasia
Most Recent Events
- 29 Jan 2019 Chemical structure information added
- 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in South Korea (PO, Capsule)
- 12 Mar 2014 GL PharmTech announces intention to submit NDA in 2017